Update in the Mucopolysaccharidoses
- 1 April 2021
- journal article
- review article
- Published by Elsevier in Seminars in Pediatric Neurology
- Vol. 37, 100874
Abstract
No abstract availableKeywords
Funding Information
- Abeona Therapeutics
This publication has 42 references indexed in Scilit:
- Immune Modulation for Enzyme Replacement Therapy in A Female Patient With Hunter SyndromeFrontiers in Immunology, 2020
- Intravenous Enzyme Replacement Therapy in Mucopolysaccharidoses: Clinical Effectiveness and LimitationsInternational Journal of Molecular Sciences, 2020
- Brain Pathology in Mucopolysaccharidoses (MPS) Patients with Neurological FormsJournal of Clinical Medicine, 2020
- Intrathecal enzyme replacement for cognitive decline in mucopolysaccharidosis type I, a randomized, open-label, controlled pilot studyMolecular Genetics and Metabolism, 2020
- Observational Prospective Natural History of Patients with Sanfilippo Syndrome Type BThe Journal of Pediatrics, 2018
- Mucopolysaccharidoses: overview of neuroimaging manifestationsPediatric Radiology, 2018
- Survival in idursulfase‐treated and untreated patients with mucopolysaccharidosis type II: data from the Hunter Outcome Survey (HOS)Journal of Inherited Metabolic Disease, 2017
- Neuropathology in Mouse Models of Mucopolysaccharidosis Type I, IIIA and IIIBPLOS ONE, 2012
- A block of autophagy in lysosomal storage disordersHuman Molecular Genetics, 2007
- Mucopolysaccharidosis types I, II, IIIA and VActa Neuropathologica, 1977